AD/02

This Topiramate/Naltrexone proprietary combination is in pre-clinical development. Preliminary evidence indicates a strong potential for substance abuse and alcohol-dependence. Based on the promise of this compound, the NIH has verbally committed to funding a phase II clinical trial for this candidate.

AD/03

This is a triple combination medication that is in pre-clinical development. Preliminary data indicate that this candidate, also, may be very promising in the treatment of alcohol and substance abuse.

Diagnostic Genetic Test

ADial Pharmaceuticals is in the process of developing genetic test that detects the presence of a single or combination of polymorphism that allow for the prediction of treatment response in alcohol-dependent individuals to medicines that act at specific serotonergic receptor sites.